Literature DB >> 11181161

Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS.

P Kazanjian1, W Armstrong, P A Hossler, C H Lee, L Huang, C B Beard, J Carter, L Crane, J Duchin, W Burman, J Richardson, S R Meshnick.   

Abstract

This retrospective cohort study was conducted to determine whether Pneumocystis carinii cytochrome b gene mutations in patients with AIDS and P. carinii pneumonia (PCP) are associated with atovaquone exposure. Portions of the P. carinii cytochrome b genes that were obtained from 60 patients with AIDS and PCP from 6 medical centers between 1995 and 1999 were amplified and sequenced by using polymerase chain reaction. Fifteen patients with previous atovaquone prophylaxis or treatment exposure were matched with 45 patients with no atovaquone exposure. Cytochrome b coenzyme Q binding site mutations were observed in 33% of isolates from patients exposed to atovaquone, compared with 6% from those who were not (P=.018). There was no difference in survival 1 month after treatment between patients with or without cytochrome b mutations (P=.14). Thus, cytochrome b mutations are significantly more common in patients with AIDS and PCP with atovaquone exposure, but the clinical significance of these mutations remains unknown.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181161     DOI: 10.1086/318835

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

Review 1.  Antiparasitic agent atovaquone.

Authors:  Aaron L Baggish; David R Hill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Circulating genotypes of Pneumocystis jirovecii and its clinical correlation in patients from a single tertiary center in India.

Authors:  Y Singh; B R Mirdha; R Guleria; S Khalil; A Panda; R Chaudhry; A Mohan; S K Kabra; L Kumar; S K Agarwal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-04-11       Impact factor: 3.267

3.  In vitro selection and in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against Pneumocystis pneumonia in mice.

Authors:  Melanie T Cushion; Peter D Walzer; Alan Ashbaugh; Sandra Rebholz; Ronald Brubaker; Jean Jacques Vanden Eynde; Annie Mayence; Tien L Huang
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Ubiquinone synthesis in mitochondrial and microsomal subcellular fractions of Pneumocystis spp.: differential sensitivities to atovaquone.

Authors:  Mireille Basselin; Shannon M Hunt; Hiam Abdala-Valencia; Edna S Kaneshiro
Journal:  Eukaryot Cell       Date:  2005-08

Review 5.  HIV-associated Pneumocystis pneumonia.

Authors:  Laurence Huang; Adithya Cattamanchi; J Lucian Davis; Saskia den Boon; Joseph Kovacs; Steven Meshnick; Robert F Miller; Peter D Walzer; William Worodria; Henry Masur
Journal:  Proc Am Thorac Soc       Date:  2011-06

6.  Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors.

Authors:  Carolyn K Dong; Sameer Urgaonkar; Joseph F Cortese; Francisco-Javier Gamo; Jose F Garcia-Bustos; Maria J Lafuente; Vishal Patel; Leila Ross; Bradley I Coleman; Emily R Derbyshire; Clary B Clish; Adelfa E Serrano; Mandy Cromwell; Robert H Barker; Jeffrey D Dvorin; Manoj T Duraisingh; Dyann F Wirth; Jon Clardy; Ralph Mazitschek
Journal:  Chem Biol       Date:  2011-12-23

Review 7.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Recapitulation in Saccharomyces cerevisiae of cytochrome b mutations conferring resistance to atovaquone in Pneumocystis jiroveci.

Authors:  Philip Hill; Jacques Kessl; Nicholas Fisher; Steven Meshnick; Bernard L Trumpower; Brigitte Meunier
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy.

Authors:  Sadhna M Shankar; Joseph J Nania
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

10.  In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.

Authors:  Pascale Meneceur; Marie-Anne Bouldouyre; Dominique Aubert; Isabelle Villena; Jean Menotti; Virginie Sauvage; Jean-François Garin; Francis Derouin
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.